性差异定义了对动脉样硬化的脆弱性
Anastasia V Poznyak1, Vasiliy N Sukhorukov2, Shuzhen Guo3
1Institute for Atherosclerosis Research, Moscow, Russia.
Clinical Medicine Insights. Cardiology
|August 2, 2023
概括
这篇评论强调了动脉样硬化中的性别差异,揭示了女性对心血管疾病进展和并发症表现出保护作用. 需要进一步的研究才能充分理解这些基于性别的机制.
科学领域:
- 心血管研究研究心血管研究
- 病理生理学 病理生理学
- 医学中的性别差异.
背景情况:
- 动脉样硬化仍然是心血管疾病的主要原因,但其潜在的机制和危险因素尚未完全阐明.
- 尽管已知的致病因素,但它们在动脉样硬化中的实施和相互作用的复杂细节仍在调查中.
- 了解风险因素如何导致动脉样硬化病原体需要进一步探索.
研究的目的:
- 巩固当前关于性别作为人类和动物动脉样硬化的生物变量作用的知识.
- 识别现有的差距,了解生物性别如何影响动脉样硬化发展及其并发症.
- 检查动脉样硬化中的炎症,血管重塑和斑块形态的基于性别的差异.
主要方法:
- 对最近关于动脉样硬化的性别差异研究的综合文献综述.
- 分析来自人类和动物模型的数据.
- 综合与炎症,血管重塑和斑块特征相关的发现.
主要成果:
- 在动脉样硬化所涉及的炎症过程中存在显著的性别差异.
- 动脉样硬化中的血管重塑模式在性别之间有所不同.
- 斑块形态表现出由生物性别影响的独特特征.
- 雌性似乎具备神经保护性质.
结论:
- 生物性别在动脉样硬化的发病和进展中起着至关重要的作用.
- 女性表现出对动脉样硬化发展和并发症的保护作用.
- 对性别特异性机制的进一步研究是有必要的,以完善心血管疾病的治疗策略.
更多相关视频
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
12.2K
06:43Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
Published on: December 7, 2013
13.8K
相关概念视频
Coronary Artery Disease I: Introduction
20
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
20
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
13
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
13
Atherosclerosis I: Introduction
10
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
10
X-linked Traits
55.0K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
55.0K
Psychoneuroimmunology: Cardiovascular Disease
52
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
52
Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
